55361-49-4

Usage

Uses

Used in Pharmaceutical Industry:
1-Ethyl-1H-pyrazol-3-amine is used as a key intermediate compound for the synthesis of various pharmaceutical drugs. Its unique chemical structure allows it to be a valuable building block in the development of new medications, potentially leading to the creation of novel therapeutic agents.
Used in Research and Development:
1-Ethyl-1H-pyrazol-3-amine is used as a research compound for studying its chemical properties and potential applications in various fields. Ongoing research aims to understand its interactions with other molecules and its potential role in the development of new drugs and materials.
Used in Chemical Synthesis:
1-Ethyl-1H-pyrazol-3-amine is used as a reagent in chemical synthesis processes, particularly in the preparation of complex organic molecules. Its presence in the synthesis can lead to the formation of new compounds with potential applications in various industries, including pharmaceuticals, materials science, and more.

InChI:InChI=1/C5H9N3/c1-2-8-4-3-5(6)7-8/h3-4H,2H2,1H3,(H2,6,7)

Upstream product

• 58793-46-7 1-ethyl-3-nitro-1H-pyrazole 
• 6629-60-3 ethylhydrazine oxalic acid salt 
• 920-37-6 2-Chloroacrylonitrile 

Downstream Products

• 935266-69-6 N-(1-ethyl-1H-pyrazol-3-yl)-4-nitro-benzenesulfonamide 
• 935266-74-3 N-(1-ethyl-1H-pyrazol-3-yl)-N-{1-methyl-3-[2-(4-phenoxy-phenoxy)-thiazol-5-yl]-prop-2-ynyl}-4-nitro-benzenesulfonamide 
• 871656-77-8 3-[((1S)-2-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-1-methylethyl)oxy]-N-(1-ethyl-1H-pyrazol-3-yl)-5-[(phenylmethyl)oxy]benzamide 
• 915770-72-8 N-(1-ethyl-1H-pyrazol-3-yl)-3-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}-5-[(phenylmethyl)oxy]benzamide 
• 1030274-16-8 C₂₄H₂₂N₈O 
• 1201934-72-6 2-[[2-[(1-ethylpyrazol-3-yl)amino]-5-(trifluoromethyl)-4-pyridyl]amino]-N-methyl-benzamide 
• 1216504-91-4 3-bromo-1-ethyl-1H-pyrazole 
• 915770-71-7 N-(1-ethyl-1H-pyrazol-3-yl)-3-hydroxy-5-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}benzamide 

Relevant academic research and scientific papers

Optimization of Novel 1-Methyl-1 H-Pyrazole-5-carboxamides Leads to High Potency Larval Development Inhibitors of the Barber's Pole Worm

A phenotypic screen of a diverse library of small molecules for inhibition of the development of larvae of the parasitic nematode Haemonchus contortus led to the identification of a 1-methyl-1H-pyrazole-5-carboxamide derivative with an IC50 of 0.29 μM. Medicinal chemistry optimization targeted modifications on the left-hand side (LHS), middle section, and right-hand side (RHS) of the scaffold in order to elucidate the structure-activity relationship (SAR). Strong SAR allowed for the iterative and directed assembly of a focus set of 64 analogues, from which compound 60 was identified as the most potent compound, inhibiting the development of the fourth larval (L4) stage with an IC50 of 0.01 μM. In contrast, only 18% inhibition of the mammary epithelial cell line MCF10A viability was observed, even at concentrations as high as 50 μM.

NEMATOCIDAL SULFONAMIDES

Disclosed are compounds of Formula 1 (see "Formula 1"), N-oxides, and salts thereof, wherein Z is O or S; and R1, R2, R3, Q and n are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling a parasitic nematode comprising contacting the parasitic nematode or its environment with a biologically effective amount of a compound or a composition of the invention.

Pyrazole glucokinase activators

Disclosed herein are pyrazole glucokinase activators of the formula (I) useful for the treatment of metabolic diseases and disorders, preferably diabetes mellitus.

HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES

Compounds of Formula (I) wherein: R1 is hydroxymethyl; R2 is selected from -C(O)NR4R5, SO2NR4R5, S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R5 is hydrogen or (1-4C)alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.

PYRIMIDINES WITH TIE2 (TEK) ACTIVITY

The invention relates to a compound of the Formula (I). or salt thereof wherein R1, R2, R3, R4, R5, R6, A, B, L, n and m are as defined in the description. The invention also relates to pharmaceutical compositions of said compounds, the use of said compounds as medicaments and in the production of an anti-angiogenic effect in a warm-blooded animal. The invention also relates to processes for the preparation of said compounds.